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Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne NE2 4HH, UKSummary that fibrosis is irreversible and the best hope therapeuticallywouldFibrosis is a common pathological process for the majority of liver
diseases which in a significant minority of patients leads to end-
stage cirrhosis and/or hepatocellular carcinoma. Data emerging
from small rodent models of chronic liver disease have demon-
strated that fibrotic extracellular matrix can be remodelled and
near-normal hepatic architecture regenerated upon cessation of
injury. Moreover, regression of liver fibrosis in these model sys-
tems can be stimulated with drugs that target the activities of
fibrogenic hepatic stellate cells. These findings are exciting as
they suggest that established fibrosis is susceptible to regression
and possibly even reversion. Alongside these experimental stud-
ies is a growing body of clinical data that suggest regression of
fibrosis may also occur in liver disease patients for whom an
effective treatment is available for their underlying liver injury.
This paper provides an up-to-date review of the currently avail-
able clinical data and also considers technical caveats that high-
light the need for caution in establishing a new dogma that
human liver fibrosis is reversible.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
The burden of chronic liver disease is rising in the UK and world-
wide.Whilst viral hepatitis remains the leading causeof liver trans-
plantation globally, the prevalence of non-alcoholic fatty liver
disease (NAFLD) has escalated over the last decade and is increas-
ingly being recognised as a cause of liver cirrhosis and hepatocellu-
lar carcinoma (HCC) [1,2]. A common pathological feature of
chronic liver disease is fibrosis which results from unregulated
wound-healing and is characterised by the progressive replace-
ment of functional hepatic tissuewith highly cross-linked collagen
I/III-rich extracellular matrix. Fibrosis perturbs both the normal
architecture and functions of the liver especially in the end-stage
of cirrhosis. Fibrosis is also considered a pre-cancerous state that
provides microenvironments in which primary tumours may
develop. The dogma prevailing in the literature until recently wasJournal of Hepatology 20
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E-mail address: Derek.Mann@ncl.ac.uk (D.A. Mann).be tohalt progression.However, there is nowmounting clinical evi-
dence that liver fibrosis can regress in a variety of liver diseases,
observed either on cessation of the cause of liver injury or treat-
ment of the underlying disease. Significant advances in our under-
standing of the pathogenesis of liver fibrosis have enabled the
identification of potential therapeutic targets but as yet, there are
no licensed anti-fibrotic therapies [3]. If fibrosis is genuinely a
reversible state then the scene is set for clinical trials that deter-
mine the ability of anti-fibrotics to promote fibrosis regression.Definition of fibrosis and cirrhosis
Fibrosis is a consequence of almost all chronic liver diseases pre-
dominantly arising from viral, alcohol-induced, autoimmune, and
metabolic aetiologies. It describes the result of a dysregulated
wound healing response driven by iterative injury and resulting
in the balance of extracellular matrix turnover favouring net
deposition. Iterative injury is vital in perpetuating this response.
The progressive accumulation of matrix ultimately leads to the
development of cirrhosis in a proportion of patients with associ-
ated important clinical sequelae.
Cirrhosis is historically a morphological definition describing
an abnormal liver architecture encompassing fibrous bands
surrounding regenerative nodules [4]. It is important to highlight
that fibrosis and cirrhosis,whilst sometimes used interchangeably,
are clinically distinct entities. Fibrosis, per se, in a pre-cirrhotic
liver, is arguably of little clinical consequence as the hepatic
reserve has not been significantly compromised at this stage.
One caveat however, is thatwhilst the increased riskofHCC is asso-
ciated with liver cirrhosis of all aetiologies, it has been recognised
that there is an increased risk of HCC in pre-cirrhotic patients in
some liver diseases. Indeed, in the context of chronic hepatitis B,
up to 40% of HCC cases occur in pre-cirrhotic patients whilst data
from the HALT-C trial indicate that approximately 17% of pre-cir-
rhotic patientswith chronic hepatitis C developHCC [5,6]. The def-
inition of cirrhosis should incorporate at least three other
important factors: firstly, disruption to the vasculaturewhich con-
tributes to the development of portal hypertension, secondly,
alteration in hepatic function which may ultimately lead to
decompensated liver disease, and thirdly, increased risk of neo-
plastic transformation, a phenomenon relevant to cirrhosis of all
aetiologies. These factors therefore translate into important clini-
cal outcomes leading to liver-related morbidity and mortality.
It has become increasingly apparent that the development of
liver fibrosis is a dynamic process with bidirectionality. Whilst12 vol. 56 j 1171–1180
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effective removal of the causative agent can result in fibrosis
regression, dual hepatic pathologies such as HIV/hepatitis C co-
infection can lead to an accelerated fibrosis progression [7,8].Assessment of fibrosis
Assessment of liver fibrosis through histological examination,
with tissue obtained through percutaneous or transjugular liver
biopsy, remains the current reference standard for quantifying
fibrosis but, as such, is imperfect. Fibrosis is scored using a non-
linear semi-quantitative scoring system, namely the METAVIR or
Ishak scoring system, assigning between 5 or 7 stages, respec-
tively. The difference in the degree of fibrosis between early stages
of these scoring systems is significantly less than that observed
between the later stages of these scales [9]. Cirrhosis is repre-
sented by stage 4 on the METAVIR scoring system or stage 6/7
on the Ishak scale. There is, however, a great deal of variation
within this classification with respect to cirrhosis, such as the
thickness of fibrous septa and nodule size. As a result, Laennac
sub-classified cirrhosis into three separate grades based on the
above features and this subclassification appears to correlate with
clinical stage and degree of portal hypertension, as measured by
the hepatic portal venous gradient (HVPG) [10]. Nagula et al. as
well as Garcia-Tsao et al. have also highlighted the need to incor-
porate clinical, haemodynamic and biological features when
developing a new sub-classification of cirrhosis [11,12].
Given that a typical liver biopsy represents a mere 1/50,000th
of the liver, it is unsurprising that sampling error can give rise to
significant variation in results. The size of the biopsy specimen
has also been shown to be important in the interpretation of
the fibrosis stage. The smaller the sample, the more the fibrosis
stage is likely to be underestimated [13]. One study showed that
Tru-cut biopsies taken laparoscopically, in duplicate, from right
and left lobes of the liver, in patients with chronic hepatitis C dif-
fered in histological assessment as either stage 3 or 4 disease in
14.5% of cases [14]. In a similar study, which included patients
with differing aetiologies, this discrepancy increased to 23.5%.
Of note, all samples met criteria of adequate size [15].
Alternatives to the liver biopsy include more attractive non-
invasive approaches including transient elastography and serum
marker panels, incorporating combinations of markers of matrix
turnover and/or markers of liver function. Other imaging modal-
ities have also gained interest including specialised magnetic res-
onance techniques and an ultrasound based technology, acoustic
radiation force impulse (ARFI) which was found to be comparable
or superior to serum markers and transient elastography in dis-
tinguishing moderate fibrosis and cirrhosis [16,17]. Each of these
methods is associated with strengths and weaknesses and perfor-
mance is variable dependent on the aetiology of the liver disease
[18,19]. No single method can provide the same information as
histological examination but combining non-invasive modalities
can differentiate between mild and significant fibrosis and poten-
tially avoid unnecessary liver biopsy in a sub-group of patients
[20]. Whilst these methods have provided some impressive
results in the analysis of cross-sectional data, there remains a
paucity of longitudinal studies to validate their use in disease
monitoring or assessment of potential anti-fibrotic therapies.
This is in part hampered by the ethics of performing serial liver
biopsies, which at present, is really the only means of validating
the use of such markers longitudinally. Unfortunately, neither of
these methods can provide the same information as a liver1172 Journal of Hepatology 2012biopsy, but if validated, could provide a very useful adjunct for
disease monitoring. Given that liver histology is a surrogate mea-
sure of clinical outcome, liver specific outcomes could be used as
a reference to assess markers [21].
Key Points
• There is increasing clinical evidence for the regression of 
improved clinical outcomes
• Histological evaluation through liver biopsy remains the 
impractical for repeated measures; combining 
non-invasive technologies, in conjunction with hard clinical 
outcomes, will be important in longitudinal evaluation of 
future treatment trials
• There is a real need for standardised reporting methods to 
liver fibrosis in a variety of liver diseases associated with
reference  standard  for  assessing  liver  fibrosis  but  is
aid interpretation of anticipated anti-fibrotic therapy trialsThe implications of utilising a less than perfect reference stan-
dard impose a real limitation on developing new technologies.
Potentially, an alternative diagnostic test may be more accurate
than liver biopsy in correctly distinguishing disease severity but
this would never be realised using the current evaluation. Indeed,
Mehta et al. have demonstrated that the measurement error of
liver biopsy itself can significantly impact on the observed diag-
nostic performance of a surrogate marker as measured by area
under the ROC curve (AUROC), potentially leading to rejection
of a perfect surrogate marker [22].Defining fibrosis regression
The interpretation of studies addressing the regression of fibrosis
relies heavily not only on defining how we measure changes in
fibrosis, but also how we analyse the resultant longitudinal data.
Histological findings with respect to regression of fibrosis are
often reported as a percentage of patients with an improved
METAVIR score, usually perceived as a 1 or 2 decrease in score,
although some studies also include those with an unchanged
score in the improved category. Other studies report a mean
fibrosis score for a subgroup of patients at each timepoint and look
for a statistically significant difference in mean scores. The statis-
tical validity of reporting longitudinal data in this manner is
flawed on two counts: firstly, the METAVIR score is a semiquanti-
tative scoring system and not a linear scale rendering a mean
METAVIR fibrosis score an unsound concept and secondly, com-
paring mean fibrosis scores at different time points loses the
changes that occur at an individual level. With the advent of
serum marker panels and other non-invasive methods, repeated
measures for individual cases become feasible rendering the latter
problem more significant. One alternative approach, particularly
useful when analysing longitudinal continuous data such as
serummarker scores, is to report changes in fibrosis as a summary
measure for each individual, for example, by measuring the area
under the curve for each case using trapezoidal integration [23].
Defining progression and regression of fibrosis is imperative
to the assessment and development of potential anti-fibrotic
therapies and for the evolution and translation of our increasedvol. 56 j 1171–1180
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understanding of the pathogenesis of liver fibrosis to targeted
therapies.Clinical evidence of regression of fibrosis
A landmark paper by Perez-Tamayo in 1979 described evidence
in both animal models and human disease for reversal of fibrosis
and cirrhosis [24]. Subsequently there have been a plethora of
studies in a range of liver diseases providing further support. Clin-
ical evidence for the regression of fibrosis can be sub-divided into
histological regression achieved through treatment of the pri-
mary disease versus deceleration of the rate of fibrosis progres-
sion in the context of accelerated fibrosers, as seen in recurrent
hepatitis C post-transplantation, HIV–hepatitis C co-infection
and patients with dual hepatic pathologies.
There is growing clinical evidence that early to moderate
fibrosis can regress and possibly even resolve in a number of liver
diseases. It is difficult to believe from a clinical perspective that
established cirrhosis may resolve to a pre-cirrhotic state. There
are however, a number of studies reporting evidence of such
reversal. This evidence is predominantly based on changes in his-
tological stage, subject to sampling error and interpretation and
should be interpreted with caution. The limitations of liver biopsy
render dissecting true regression from sampling error a chal-
lenge. Clinical outcomes of such patients may be more reliable
as a determinant of regression of disease and indeed, histological
assessment is a surrogate marker for clinical outcome.
This leads us to ask: Does an improved clinical outcome
equate with histological regression? It is conceivable that stasis
or failure of disease progression, driven by removing the causa-
tive agent or treating the underlying aetiology, may in fact be
associated with an improved outcome. Indeed, a number of stud-
ies have reported a reduced risk of neoplastic transformation in
treated chronic hepatitis C [25–28].Is there any evidence of cirrhosis regression?
Regression of cirrhosis is still a debated topic. Reports of apparent
cirrhosis regression are few in number and mostly not correlated
with clinical outcomes. Wanless et al. presented serial biopsies
from a patient with hepatitis B following treatment with lamivu-
dine [29]. Histology revealed apparent disease regression. The
results from one patient alone of course do not rule out the pos-
sibility of sampling error. In addition, 52 explant cirrhotic livers
removed at transplantation were examined for features of regres-
sion of cirrhosis. Unfortunately, the findings were not correlated
with clinical outcomes.
Serpaggi examined histological evidence for regression of cir-
rhosis following disease-specific therapy in a range of liver dis-
eases including HCV, HBV and autoimmune cirrhosis [30].
Interestingly, 14/113 patients (12.4%) demonstrated post-treat-
ment regression of their disease, a frequency consistent with
the sampling error observed in Regev’s study [14]. All 14 patients
repeat biopsies were reported as stage F1 or F2, that is, consistent
with regression by more than one stage of fibrosis. According to
Regev’s study, the frequency of a scenario where a biopsy may
be reported as F3–F4 in one lobe and F0–F2 in the other lobe
was still 9.7%. Serpaggi’s study therefore unfortunately does not
dispel all doubt that the apparent histological improvement is
an accurate reflection of change in fibrosis.Journal of Hepatology 2012Evidence of liver fibrosis regression in specific liver diseases
In this section, we will address, in turn, evidence of regression of
fibrosis for specific liver diseases with attention to clinical
outcomes.
Hepatitis C
The majority of evidence for regression of liver fibrosis has been
observed in the context of treatment of chronic hepatitis C (CHC).
Successful eradication of the virus effectively removes the under-
lying aetiology of the liver disease. Around 15% of patients with
CHC spontaneously resolve their infection without antiviral treat-
ment. With the current licensed treatment regime of pegylated
interferon in combination with ribavirin, sustained virological
responses (SVRs) of between 50% and 60% can be achieved.
In this section we will discuss the evidence for fibrosis regres-
sion focussing on histological evidence. In addition to the limita-
tions of liver biopsy previously discussed including variation of
results with specimen size, there are perhaps other caveats to
be considered in the context of hepatitis C. Two studies examin-
ing the natural history of CHC demonstrated a spontaneous
decrease in fibrosis score by two stages in up to 14% of patients
which may again be a reflection of sampling error [31,32].
A number of studies have performed serial liver biopsies on
patients treated for CHC. In many of these studies, post-treatment
biopsies were performed at a relatively short time interval fol-
lowing end of treatment, often between 6 months and 1 year.
Whilst improvements in inflammatory scores were often quite
marked, perhaps unsurprisingly, changes in fibrosis scores were
less frequently observed. The largest of these studies was
reported by Poynard et al. who retrospectively pooled individual
data from four randomised CHC treatment trials including 10 dif-
ferent treatment regimes of interferon, pegylated interferon and
ribavirin. Three thousand and ten patients included in this study
had paired pre-treatment and post-treatment liver biopsies with
a mean time between biopsies of 20 months. Results were
reported as percentage of patients with either a 1 stage increase
or decrease in fibrosis as well as fibrosis progression rate per year
[33]. The overall histological response was an improvement in
fibrosis stage in 20% of patients, no change in 65% and an increase
in fibrosis stage in 15%. All patients had a decrease in fibrosis pro-
gression rate post-treatment, irrespective of treatment regime,
but with statistically significant lower progression rates observed
in responders compared to non-responders (p <0.001). An
increase in fibrosis was also less frequently observed in those
patients who attained SVR (7% compared to 17% of relapsers
and 21% of non-responders).
Given that the development of fibrosis can progress over many
years, intuitively it would seem more appropriate to re-examine
liver histology to assess for fibrosis regression at a greater time
interval following end of treatment. Indeed, there are a number
of studies which have achieved this and correlated results with
clinical outcomes (Table 1). The limitations of the majority of
these studies which have reassessed histology greater than
18 months post-treatment are that reporting methods vary
between studies which hamper interpretation. Most of these
studies were also performed over a decade ago when interferon
monotherapy was standard treatment. The largest and most
recent of these studies by George et al. enrolled 150 patients
who had all attained SVR following treatment for CHC withvol. 56 j 1171–1180 1173
Table 1. Histological, virological, and clinical evidence for the regression of liver fibrosis in patients treated for chronic hepatitis C. Cohort studies of treated chronic hepatitis C patients with long term follow up
biopsies (minimum 18 months after end of treatment).
Study, 
[Ref.]
n Virologic 
response at 
study entry
Genotype n (#) Fibrosis stage at index 
biopsy
Timing of 
repeat biopsy 
(mean)
Treatment 
regime
Length of 
follow-up 
(mean)
Histological response on repeat biopsy Virologic response 
(end of study)
Clinical response
Tsubota 
(1997),
[94]
RT study
93 All 
SVR
GT 1: 
42%
93
(combined grps A, B and C): 
2.3 ± 0.4
Patients divided into 3 grps 
according to length of time 
between EOT and 
post-treatment biopsy: 
Grp A (<1 yr), 
Grp B (1-2 yr), 
Grp C (≥2 yr)
15.2 ± 6.7 mo 
after EOT
Standard 
IFN-α course
53.6 ± 14.0 
mo (vs. pretreatment score 2.3 (p <0.0001))
For Grp C where post-treatment biopsies 
were taken ≥2 yr after EOT the decrease in 
p = 0.0024
No reported
virologic relapses 
during follow-up
n.r.
Marcellin 
(1997),
[55]
P cohort 
study
Patients 
included  
from 6 
RCTs of 
IFN-α
80 All 
SVR 
GT 1: 
33%
69 Cirrhosis: 
n = 5
No cirrhosis: 
n = 75
2.2 ± 1.3 yr 
after EOT 
in 48/69 
patients
IFN-α
(different 
regimes 
according to 
treatment trial)
4 yr
 
Improved histology in 94% of patients 
(decrease ≥2 points on Knodell score)
NB: Total Knodell score - activity as well as 
1 patient had Deaths: n = 1 (from 
peritoneal 
carcinomatosis related 
to colon cancer)
No patients 
developed HCC or 
decompensated liver 
disease
Reichard 
(1999),
[78]
P cohort 
study
26 All 
SVR
GT 1:
41%
23 Scheuer 0-3: 
n = 22
Cirrhosis: 
n = 4 (all 
compensated)
pre-treatment  = 1.9
5 ± 1.8 yr 
after EOT
IFN-α course 
(duration of 
course varied 
between trials)
5.4 ± 1.6 yr 
after EOT (vs. pre-treatment score 1.9 (p = 0.0008)) 
All 4 cirrhotic patients had a decrease in 
biopsy
2/26 had a late 
virological relapse 
>2 yr after EOT
No decompensated 
cirrhosis 
HCC/liver-related 
deaths not 
George 
(2008),
[29]
P cohort 
study
150 All 
SVR 
GT 1: 
n = 75 
(53%)
60 
(49$)
Scheuer 
stage 1: n = 27
Scheuer 
≥stage 2: n = 116
Total: n = 146
4 yr 
after EOT
IFN-α2b + RBV:
n = 146
PEG-IFN-α2a + 
RBV: n = 4
5 yr 
(reported as 
median 
of 65 mo)
39/49 (80%) had a No patients with HCC development: 
n = 2 (both cirrhotic 
pre-treatment)
No patients developed 
decompensated liver 
disease
Deaths: n = 1 
(recurrent liver cancer 
post OLT)
Toccaceli 
(2008)
[93]
RT 
multi-
centre 
study
112 Sustained 
responder*: 
n = 87
Relapsers: 
n = 25
GT 1: 
Sustained 
responder 
grp 55%;
 
Relapsers 
80%
112
Sustained responder 
Grp (n = 87): 1.2 ± 1.1
Relapsers 
(n = 25): 1.6 ± 1.2
2.5 ± 1.2 yr 
after EOT 
(range 12-76 
mo) in
sustained 
responder grp
2 ± 0.7 yr after 
EOT (range 
12-31.4 mo) in 
relapsers
Standard 
IFN-α course
3 yr 
minimum
29/66 (44%) of sustained responder grp with 
an unchanged score. None had increased 
score
score had decreased score after 
treatment, 15 had unchanged score and 3 
had increased score (p <0.001 vs. SVR grp)
No late virologic 
relapses in 
sustained 
responder grp
No liver-related deaths, 
decompensated 
cirrhosis or HCC 
occurred
Mean Scheuer fibrosis score
Mean fibrosis score
Mean Knodell fibrosis score:
3/21 relapsers with abnormal index fibrosis
abnormal index fibrosis score had decreased
fibrosis score post-treatment, 37 (56%) had
10/12 (83%) patients with advanced fibrosis/
cirrhosis had decreased fibrosis scores
decrease in fibrosis stage
fibrosis stage on post-treatment
Mean fibrosis score post-treatment = 1.0
fibrosis
fibrosis stage was also significant
Mean Scheuer fibrosis score: 1.5 ± 0.7
specifically reported
definite relapse
definite relapse
⁄Sustained responder = patients with persistently normal ALT and negative serum HCV RNA levels at EOT and during following 12 months. RT, retrospective; P, prospective, RCT, randomised controlled trial; n.r., not
reported.
#With paired liver biopsies.
$With blinded analysis.
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follow up for 5 years monitoring histological, virological, bio-
chemical and clinical outcomes [34]. One hundred and forty-six
patients had a pre-treatment biopsy and 60 patients had a post-
treatment biopsy performed at a mean of 4 years after end of
treatment (EOT); 48 of these patients had paired pre- and post-
treatment biopsies available for re-scoring by a pathologist
blinded to clinical information. Patients (40/49) had decreased
fibrosis scores on repeat biopsy. Interestingly, two patients with
cirrhosis pre-treatment developed HCC during follow-up and
one patient died from recurrent liver cancer post-OLT. This high-
lights that treated patients with SVR are still at risk of HCC devel-
opment. Other studies also support the association between SVR
and improved clinical outcomes including a decrease in liver
related death and decompensated disease [35,36]. Mallet et al.
describe a cohort of 96 patients with CHC cirrhosis who under-
went repeat liver biopsy following interferon-based treatment
[37]. The subgroup who attained SVR had significantly fewer
liver-related deaths and events compared to non-responders.
Moreover, 18 patients were reported to have regression of cirrho-
sis on repeat biopsy performed at a median of 17 months post-
EOT and of those, 17 had attained SVR. In this subgroup, there
were no reported liver-related deaths or events. Further evidence
supporting improved clinical outcomes secondary to virologic
response include a 12 year follow up study of 218 patients with
compensated cirrhosis which showed that patients attaining
SVR did not develop de novo oesophageal varices compared to
22 of the 69 untreated subjects [38]. In addition, a study by Rob-
erts et al. demonstrated that treatment of compensated CHC cir-
rhosis with a standard pegylated interferon and ribavirin regime
may invoke a significant reduction in hepatic venous pressure gra-
dient in sustained responders compared to non-responders [39].
Hepatitis B
Chronic hepatitis B (CHB) is a significant worldwide problem
with up to 25% of patients developing HCC. Standard treatments
include interferon-alpha (IFN), pegylated interferon PEG-IFN
alpha 2a and nucleos(t)ide analogues (NUCs) [40]. A number of
studies have shown that HBV DNA suppression is associated with
biochemical and histological response and importantly, there is
evidence that these surrogate markers correlate with improved
long term clinical outcomes.
Interferon has been used in the treatment of CHB since the
1980s and typically approximately 33% of patients will attain
biochemical and virological response following a finite treatment
course [41]. Interferon therapy has been shown to reduce fibrosis
progression in HBeAg-positive patients, with a greater response
seen in those who sustain HBeAg seroconversion, as well as in
HBeAg negative patients with sustained virological response
[42–45]. In addition to a decrease in fibrosis progression, clinical
outcomes also improve. The long term clinical response to inter-
feron treatment has been recently addressed by a meta-analysis
evaluating the effects of interferon treatment in 975 patients ver-
sus 1147 untreated controls from 11 studies with a 6 year mean
follow up. Interferon treatment was found to decrease the risk of
hepatic events and cirrhotic complications with the greatest ben-
efit seen in sustained responders [46].
Long term therapy with nucleoside analogues has also been
shown to improve liver fibrosis and disease progression. A recent
study evaluating the long term benefits of entecavir in the treat-
ment of CHB in nucleoside naïve patients found a reduction inJournal of Hepatology 2012liver fibrosis by at least 1 point on the Ishak fibrosis score in
88% of the 57 patients from the 293 enrolled with serial biopsies
treated with entacavir for 6 years [47]. This was associated with
both a virological and biochemical response although long term
clinical outcomes were not reported with respect to incidence
of HCC. Similarly, histological improvement including fibrosis
regression has been seen following long-term treatment with
lamivudine or adefovir but resistance mutations are more com-
mon with these agents [48,49].
NAFLD
Non-alcoholic fatty liver disease (NAFLD) encompasses a spec-
trum of disease including simple steatosis, steatohepatitis, liver
fibrosis and cirrhosis. There are currently no licensed therapies
for NAFLD and management strategies are based on targeting risk
factors and detecting patients with significant fibrosis and cirrho-
sis. Whilst there have been a number of studies assessing the
potential benefits of various pharmacological agents in NAFLD,
the majority of these studies have been relatively small scale
with short follow-up and have not been designed to specifically
address effects on liver fibrosis [50].
Weight loss, preferentially achieved through lifestyle modifi-
cation, is often the first-line management strategy in this patient
group. Weight loss is often associated with beneficial effects on
multiple components of the metabolic syndrome. Histological
improvements have also been observed, particularly with respect
to steatosis, but evidence of fibrosis regression is less convincing
[51–56]. A recent randomised controlled trial assessing the effect
of weight loss by lifestyle intervention on non-alcoholic steato-
hepatitis (NASH) over a 48 week period in 31 overweight patients
demonstrated significant improvements in the NASH histological
activity score following an average weight loss of 9.3% but failed
to show a significant change in fibrosis [51].
With respect to surgical intervention, there are currently no
random controlled trials (RCTs) evaluating bariatric surgery ver-
sus lifestyle modification or placebo. Dixon et al. published a case
series of 36 patients with NAFLD (23 patients with NASH) who
had paired liver biopsies before and after weight loss following
laparoscopic gastric band placement [57]. Index biopsies were
obtained at the time of surgery with follow up biopsies taken
either laparoscopically or percutaneously at a mean of 26 months
following the first biopsy. A mean weight loss of 34 kg was
achieved with mean BMI decreasing from 47 to 34. Of the 23
patients with NASH on index biopsy, 19 patients had histological
remission of NASH following weight loss. With respect to fibrosis,
there were 10 patients with stage 3 fibrosis on index biopsy and
all but 1 of these patients had a decrease in fibrosis stage, includ-
ing seven patients with complete fibrosis regression to stage 0 on
repeat biopsy. However, surgical intervention may not always be
beneficial as reports of extreme weight loss following bariatric
surgery have been associated with liver-related morbidity. From
21 cohort studies evaluated in a recent Cochrane review there
were reports of histological deterioration following bariatric sur-
gery including increased fibrosis [58].
Alcoholic liver disease
Evidence for regression of fibrosis in alcoholic liver disease is lim-
ited. Alcoholic liver disease is the leading cause of liver transplan-
tation in the UK yet there are surprisingly few studies examiningvol. 56 j 1171–1180 1175
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histological change in this disease. Conversion of micronodular to
macronodular cirrhosis was reported in 1983 by Fauerholdt et al.
in a controlled trial of prednisolone in 156 patients with cirrhosis
[59]. Seventy-five patients had histological evidence of micronod-
ular cirrhosis on biopsy with apparent conversion to macronodu-
lar cirrhosis at autopsy in 68 cases.
Results from RCTs assessing the effects of pharmacological
therapy on alcoholic fibrosis and cirrhosis have been disappoint-
ing. A Cochrane Intervention Review assessing the effect of
colchicine for alcoholic and non-alcoholic liver fibrosis and cir-
rhosis from 15 randomised controlled trials concluded there
was no statistically significant improvement in any significant
clinical outcome, including liver histology, assessed from the
results of four RCTs [60]. It should be noted that only one of
these RCTs included patients solely with alcoholic liver disease,
one RCT assessed patients with hepatitis B and the remaining
RCTs included mixed aetiologies.
What has been addressed to a limited degree, however, is the
effect of abstinence on clinical outcome. One of the earliest stud-
ies to demonstrate an increased survival in patients with alco-
holic cirrhosis following abstinence was described by Powell
[61]. This study examined 283 cases of histologically proven
‘Laennec’s cirrhosis’ or micronodular cirrhosis between 1951
and 1963. Survival analyses showed a statistically significant dif-
ference between abstainers (63% 5 year survival) and those who
continued to drink (40.5% 5 year survival) (p <0.001). Surpris-
ingly, not all subsequent studies have supported abstinence as
a factor influencing prognosis. Verrill et al. reported that the ben-
efits of abstinence may not be realised immediately following
abstention and postulate that a number of studies failing to iden-
tify an association between abstinence and improved prognosis
may be due in part to a relatively short follow up [62]. In their
study, Verrill et al. followed 100 patients with alcoholic cirrhosis
for 7 years from baseline histological assessment and found
abstinence, assessed 1 month post-biopsy, was associated with
a significant improvement in long-term survival [62]. Abstinence
at 1 month post-biopsy was found to be an excellent predictor of
long term abstinence with 98% of patients remaining abstinent at
5 years. They found that the benefits of abstinence were realised
after longer follow-up with statistically significant difference in
5 year survival rates between abstainers (75% survival) versus
drinkers (50% survival) (p <0.002). Surprisingly, patients with
milder rather than severe cirrhosis as graded by the Laennec
grading system had a worse survival rate. With respect to other
clinical outcomes, available evidence suggests that abstinence
does not guard against HCC development and that HCC can occur
in pre-cirrhotic patients [63–65].
One alternative prognostic measure of outcome is the assess-
ment of hepatic venous pressure gradient. Vorobioff et al. assessed
30 patients with alcoholic cirrhosis and portal hypertension with
no previous history of gastrointestinal haemorrhage over a
42 month period [66]. All patients were abstinent from alcohol
for aminimumof 4 weeks at the start of the studybut nine patients
subsequently failed to abstainwhenassessed at the first follow-up.
Repeated portal pressure measurements were taken and fre-
quency of variceal haemorrhage and hepatic mortality recorded.
Although limited by its small sample size, abstinence in this study
was associated with a marked improvement in Child Pugh’s score
and a significant decrease in portal pressurewhich correlatedwith
a reduction or disappearance of oesophageal varices, decreased
risk of variceal haemorrhage and increased survival rate.1176 Journal of Hepatology 2012Autoimmune liver disease
Evidence for fibrosis regression in autoimmune liver disease is
limited predominantly to small scale case series and case reports.
The largest study to date by Czaja et al. retrospectively examined
325 histological specimens from 87 patients treated with one of
two regimens: dual therapy with prednisolone and azathioprine
or higher dose prednisolone as a single agent [67]. Following
the index biopsy, indications for repeat liver biopsy were treat-
ment failure or following remission, prior to discontinuation of
therapy. Ishak fibrosis scores decreased by 1–6 points in 46
patients (53%) over 57± months follow up and 30 of these
patients had a decrease in score of at least 2 points. Fibrosis
scores remained unchanged in 23 patients over 62 ± 12 month
follow up. Improvements in fibrosis score were commonly
observed where patients had an improvement in histological
activity indices. With respect to cirrhosis, 14 patients had histo-
logical cirrhosis on index biopsy whereas only 10 patients were
reported as having cirrhosis at the end of follow up.
Other reports of cirrhosis regression include a case report of a
42 year old female with autoimmune hepatitis and cirrhosis on
open-liver biopsy who was treated with prednisolone and azathi-
oprine. She underwent laparotomy with wedge liver biopsy
14 years later with apparent complete resolution of cirrhosis
[68]. Dufour et al. also reported 8 patients with autoimmune hep-
atitis and either cirrhosis or extensive fibrosis on index biopsy
who responded to medical therapy with apparent reduction in
fibrosis scores on repeat biopsy [69]. The mean fibrosis score
decreased from 3.3 to 0.8 at a median biopsy interval of
47 months. Again these results must be interpreted in the context
of the limitations of liver biopsy.
Primary biliary cirrhosis (PBC)
The only approved medical treatment for PBC is ursodeoxycholic
acid (UDCA) [70]. Unfortunately, many of the trials evaluating
UDCA were poorly designed. A Cochrane Review exaluating 16
RCTs of UDCA versus placebo identified almost half of these trials
had a high risk of bias and concluded that UDCA did not signifi-
cantly improve liver histology and had no demonstrable effect
on improving mortality [70].
The role of immunosuppressive agents in PBC remains contro-
versial. A number of studies evaluating methotrexate have had
conflicting results and raised concerns that methotrexate may
worsen mortality [71–73]. The largest RCT to date (PUMPS trial)
was terminated prematurely due to futility [74]. Kaplan conducted
a prospective case study describing 5 out of 19 pre-cirrhotic
patients who achieved disease remission following low dose
methotrexate for a minimum of 6 years [75]. Two of the five
patients’ fibrosis score decreased by 2 points (4 point scale) and
the remaining three patients’ scores decreased by 1 point. More
recently Kaplan et al. described a much larger case series of 91
PBC patients who failed treatment with UDCA and were subse-
quently treated with 6 months of colchicine followed by metho-
trexate if alkaline phosphatase levels failed to fall [76]. Patients
were on combination therapy with the three agents for a mean
of 2.2 years and underwent a minimum of three liver biopsies.
Whilst the response to methotrexate was heterogeneous, the
results suggested that 80% of patients either partially or com-
pletely responded to treatment. Mean METAVIR fibrosis scores
significantly decreased from 3 to 2 with a mean interval betweenvol. 56 j 1171–1180
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third and fourth biopsies of 3.5 years. It should be emphasised
however that the study was not a randomised controlled trial
and its design is a major limitation with respect to data
interpretation.Hereditary haemochromatosis
Case reports identifying regression of fibrosis and even cirrhosis
following venesection in patients with hereditary haemochroma-
tosis date back to the 1960s [77]. The largest study to date
reported by Niederau followed a cohort of 251 patients with hae-
mochromatosis over a 14 year period [78]. All patients had index
biopsies and 185 patients had one or more repeat biopsies fol-
lowing iron depletion. Fibrosis was graded using a scoring system
described by Loreal et al. and Deugnier et al.with four stages from
0 which includes septal fibrosis to 3 which includes cirrhosis
[79,80]. Forty-two (23%) patients (10 stage 1, 20 stage 2 and 12
stage 3) had a decrease in fibrosis stage and only two patients
had an increased fibrosis stage on repeat biopsy. The patients
were recruited from two hospitals in Germany with some varia-
tion in biopsy technique between centres; the majority of biop-
sies were undertaken using ultrasound guidance in one centre
compared with the majority performed laparascopically in the
second hospital. As well as an improvement after treatment in
both nonspecific symptoms and biochemical parameters, namely
ALT, subgroup analyses to assess the effect of iron removal dem-
onstrated that the prognosis of patients receiving less than 80
phlebotomies to achieve iron depletion was significantly better
than those patients requiring >80 phlebotomies to completely
remove iron. Survival was also diminished in patients who could
not be depleted of iron after >80 phlebotomies. 21/251 patients,
all with cirrhosis, developed HCC and interestingly, 17 of these
patients had documented iron depletion. This again highlights
that removal of the causative agent of liver disease is not always
protective against development of HCC.
The most recent study addressing reversibility of liver fibrosis
assessed histological outcome following venesection in 36 cases
of C282Y homozygotes with documented F3 or F4 fibrosis on
index biopsy [81]. All biopsy specimens were a minimum of
10 mm with six portal tracts with regression of fibrosis defined
as a decrease of 2 points on the METAVIR score. Sixty-nine per-
centage of patients with F3 fibrosis on index biopsy were
reported as attaining histological regression compared to 35% of
patients with F4 staging on initial biopsy. Whilst 69% is a respect-
able percentage of patients to achieve regression and is likely to
supersede the proportion of patients inaccurately staged due to
sampling error, the study is limited by its small sample size.
Other limitations of this study include a recruitment bias, varia-
tion in biopsy size and lack of correlation of histology with hard
clinical outcomes.
Wilson’s disease
Wilson’s disease is rare affecting approximately 1 in 30,000 in
many populations [82]. To date there have been seven case series
examining serial liver histology since 1975 [83–89]. These studies
are heterogeneous with respect to treatment regimes and patient
populations, some focussing solely on paediatric patients. The
most recent study by Cope-Yokoyama et al. reported serial histol-
ogy on a group of 12 patients with Wilson’s disease who had
received either zinc and/or penicillamine treatment with meanJournal of Hepatology 2012follow up of 5 ± 3 years [83]. On index biopsy there were no cir-
rhotic patients; seven patients had stage 0 fibrosis, three had stage
1 and two had stage 2 fibrosis. Half of these patients showed
worsening of histology on repeat biopsy and half had improved
fibrosis or stable fibrosis. There was no correlation between the
type of treatment received and histological response.
Cirrhosis regression remains controversial. A case report by
Falkmer et al. describes apparent cirrhosis reversal in a 10 year
old girl following treatment ofWilson’s diseasewith penicillamine
for 2 years [90]. Whilst sampling error must always be considered
when interpreting results, in this particular case 3 surgical liver
biopsy specimenswere taken both before and after treatmentwith
unified results in both groups. The liver was visualised on both
occasions at laparatomy andwas reported as moderately enlarged
with a finely nodular surface as well as evidence of ascites (2 l
drained) pre-treatment whilst on repeat laparatomy, the liver
was only slightly enlarged with a smooth surface. Pre-treatment
histology confirmed a nodular cirrhosis whilst post-treatment
biopsies showed no fibrosis and near-normalisation of the paren-
chyma. The apparent histological improvement correlated with
both a biochemical and a clinical improvement, the latter evi-
denced by resolution of ascites and peripheral oedema, normalisa-
tion of an electroencephalograph and resolution of ocular
pathology.Anti-fibrotic therapies
As our understanding of the pathogenesis of liver fibrosis
increases, a number of novel targeted approaches to treat liver
fibrosis are being explored [91–93]. Targeted approaches include
firstly, molecular targets paramount to liver fibrogenesis and/or
fibrolysis pathways such as anti-TIMP-1 and anti-PDGF-b recep-
tor blocking antibodies and secondly, targeted drug delivery to
key fibrogenic cells within the liver such as hepatic stellate
cell-targeted drug delivery through vitamin A-modified lipo-
somes [94].
Whilst the majority of novel targeted approaches to treat liver
fibrosis are still experimental, there are a number of clinical stud-
ies in progress focussing predominantly on repositioned agents
already licensed for other clinical indications. These include
angiotensin II receptor blockers whose antifibrogenic properties
have been characterised in animal models. Unfortunately, results
from a recent large-scale RCT evaluating angiotensin blocking
agents over a 3.5 year period in patients with chronic hepatitis
C have not been as promising as hoped [95].
What remains uncertain is whether anti-fibrotic therapy per
se will result in positive clinical outcomes. There remain many
unanswered questions: Would anti-fibrotic therapy decrease
the risk of neoplastic transformation in those with advanced
fibrosis/cirrhosis? Conversely, could anti-fibrotic therapy actually
increase the risk of neoplastic disease? As discussed in Fried-
man’s recent review, there is as yet there no proof of concept trial
demonstrating the positive clinical effects of specifically targeting
and decreasing liver fibrosis in man [96].Conclusions
There is a growing portfolio of published work suggestive that
liver fibrosis can regress in all chronic liver diseases, regardlessvol. 56 j 1171–1180 1177
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of aetiology, on removal of the causative agent or treatment of
the disease. However, limitations of liver biopsy including sam-
pling error and interpretation of results subject to intra- and
inter-observer variation mean that distinguishing real changes
in fibrosis longitudinally is a challenge. The most convincing evi-
dence for the regression of liver fibrosis derives from large-scale
studies of antiviral therapies for the treatment of chronic hepati-
tis C. Long-term follow up studies indicate that regression of liver
fibrosis is associated with improved clinical outcomes so
strengthening the perceived histological regression as a real phe-
nomenon. Cirrhosis regression however remains a controversial
topic and evidence is limited mainly to individual cases subject
to the limitation of liver biopsy.
Defining universal parameters for the assessment of liver
fibrosis is a funnel-neck to our development of anti-fibrotic ther-
apies. Longitudinal assessment using a combination of liver
biopsy with non-invasive testing and clearly defined clinical
end-points should aid interpretation of results. There is a real
need for universal standardised reporting methods to aid inter-
pretation and comparison of potential anti-fibrotic therapies. As
yet, there is still no proof of concept trial confirming that anti-
fibrotic therapy will result in positive clinical outcomes. Indeed,
it is paramount that potential therapies targeting matrix degra-
dation and liver regeneration do not increase the risk of neoplas-
tic transformation.Conflict of interest
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